1,550 Shares in Charles River Laboratories International, Inc. $CRL Acquired by Claret Asset Management Corp

Claret Asset Management Corp purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,550 shares of the medical research company’s stock, valued at approximately $235,000.

Other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group boosted its holdings in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after buying an additional 86 shares during the period. Cromwell Holdings LLC raised its holdings in Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management acquired a new position in Charles River Laboratories International during the 2nd quarter worth $29,000. Allworth Financial LP boosted its holdings in Charles River Laboratories International by 172.7% during the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 190 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Charles River Laboratories International in the second quarter valued at about $56,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $176.42 on Tuesday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $203.01. The company has a market capitalization of $8.68 billion, a P/E ratio of -132.65, a P/E/G ratio of 4.83 and a beta of 1.53. The stock has a 50 day moving average of $172.14 and a two-hundred day moving average of $160.57. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International’s revenue was down .5% on a year-over-year basis. During the same period in the prior year, the company posted $2.59 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CRL. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $178.00 to $199.00 in a research report on Thursday, November 6th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a report on Monday. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $190.86.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).